Borosil Scientific Limited has scheduled its 35th Annual General Meeting for Friday, September 25, 2026. The meeting will be conducted through Video Conferencing or Other Audio-Visual Means.

The event is scheduled to begin at 11:00 am IST. This arrangement complies with the Companies Act, 2013 and SEBI Listing Regulations.

Voting and Record Dates

Remote e-voting will commence on Tuesday, September 22, 2026, at 9:00 am IST and conclude on Thursday, September 24, 2026, at 5:00 pm IST. Members can also vote electronically during the AGM.

The cut-off date for determining eligibility to attend the meeting and exercise voting rights is Friday, September 18, 2026. Only members recorded in the Register of Members or Register of Beneficial Owners as on this date are entitled to participate.

Annual Report Distribution

The Annual Report for FY26, including the Notice of the AGM, will be sent electronically to members holding shares as on Friday, August 21, 2026, who have registered email addresses with the Registrar to an Issue and Share Transfer Agent or Depositories.

The report will also be available on the company website. Members without registered email addresses will receive letters containing a web link to access the documents, in compliance with Regulation 36(1)(b) of the SEBI Listing Regulations.

Borosil Scientific Limited reported a dramatic turnaround in profitability for the quarter ended June 30, 2026 (Q1FY27), with standalone net profit surging 1,390% year-on-year (YoY) to ₹6.84 crore. The Mumbai-based manufacturer of laboratory glassware and process systems also saw its consolidated net profit rise to ₹4.36 crore, reversing a consolidated loss of ₹42.10 lakh recorded in the corresponding period of FY26. This significant improvement underscores the company’s operational recovery, margin expansion, and the positive impact of excluding exceptional one-time charges that weighed on the previous year’s figures.

The Board of Directors approved the unaudited financial results on August 3, 2026. The results were reviewed by Chaturvedi & Shah LLP, the company’s statutory auditors, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, the company released an investor presentation on August 5, 2026, under Regulation 30 of the same regulations, highlighting its strategic positioning in the scientific instruments sector. The Board also approved amendments to its Employee Stock Option Plans (ESOPs), specifically the Special Purpose Employee Stock Option Plan 2023 and the BSL ESOS, subject to shareholder approval. These amendments allow for share allotment via a trust route and increase the maximum discount percentage for new option grants from 10% to 20%.

Financial Performance

Standalone revenue from operations rose 12.2% YoY to ₹99.90 crore, up from ₹89.01 crore in Q1FY26. Other income stood at ₹2.80 crore, contributing to a total income of ₹102.69 crore. Total expenses increased to ₹93.38 crore from ₹84.79 crore in the prior year period, driven primarily by higher employee benefits expense and other expenses. EBITDA grew 15.3% YoY to ₹11.50 crore, reflecting improved operating leverage.

On a consolidated basis, revenue from operations grew 11.2% YoY to ₹106.75 crore. The group reported a profit before tax of ₹5.98 crore, compared to a pre-tax loss of ₹4.08 crore in the previous year. Consolidated net profit attributable to owners of the company was ₹4.37 crore. Consolidated EBITDA expanded significantly by 50.1% YoY to ₹8.70 crore.

Segment Analysis

The scientific laboratory glass and equipment segment remained the primary growth driver. Standalone revenue from this segment increased 6.3% YoY to ₹59.83 crore, with segment profit rising to ₹12.54 crore. In contrast, the glassware segment, which includes pharmaceutical primary packaging, saw standalone revenue rise 19.4% to ₹38.36 crore, but the segment remained marginally profitable with a profit of ₹0.19 crore, compared to a loss of ₹2.40 crore in Q1FY26.

Consolidated segment revenue for the scientific division reached ₹66.68 crore, while the glassware segment contributed ₹38.36 crore. The 'Others' segment, comprising filter paper and related items, generated ₹1.71 crore in revenue.

What the Numbers Show

The dramatic improvement in net profit is largely attributable to the absence of exceptional items in the current quarter, whereas Q1FY26 included an exceptional expenditure of ₹6.61 crore towards a Voluntary Retirement Scheme (VRS) at the Nashik plant. Excluding these one-time costs, the operational profit before tax has improved significantly. Furthermore, gross margin pressure appears to have eased, as cost of materials consumed grew at a slower pace than revenue. The company also benefited from a reduction in finance costs, which fell to ₹0.10 crore from ₹0.18 crore YoY on a standalone basis.

The approved ESOP amendments signal management’s intent to retain talent through more flexible equity compensation structures. By allowing share acquisition via a trust route and increasing the discount limit, the company aims to enhance the attractiveness of its employee benefits program without immediate dilution from primary issuance. Shareholders will vote on these changes in the upcoming general meeting. The investor presentation highlights Borosil Scientific’s position as a leader in laboratory glassware, leveraging the 'Make in India' initiative and global shifts toward localized manufacturing to capture market share.